Seer Stock Price, News & Analysis

Seer, Inc. (Nasdaq: SEER) is a life sciences company focused on deep, unbiased proteomics. According to company disclosures and recent press releases, Seer describes itself as a pioneer and trusted partner for proteomic insights that emphasize scale, speed, precision, and reproducibility compared with traditional proteomic methods. The company’s Class A common stock trades on The Nasdaq Global Select Market under the ticker symbol SEER, and Seer is based in Redwood City, California.

Seer’s core offering is the Proteograph Product Suite, which the company identifies as its primary platform for enabling deep, large-scale proteomic analysis. The Proteograph Product Suite integrates several components that Seer highlights repeatedly in its public communications: proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software. By combining these elements into a single workflow, Seer aims to address challenges it attributes to conventional proteomic technologies, such as inconsistent data, limited throughput, and operational complexity.

In its public statements, Seer emphasizes that its workflow is designed to reveal biological insights that other proteomic approaches have struggled to access. The company characterizes its platform as enabling deep, unbiased proteomic profiling at a scale suitable for population-level and translational research. Seer also notes that its products are for research use only and are not intended for diagnostic procedures, positioning the business squarely within the research tools and technology segment rather than clinical diagnostics.

Seer’s technology is applied in a variety of research contexts, as reflected in scientific meetings and collaborations described in its news releases. The Proteograph Product Suite has been used in studies spanning cardiovascular disease, oncology, aging biology, and other areas of human disease research. Seer reports that its platform supports deep plasma and tissue proteomics, biomarker discovery, and the exploration of protein isoforms and extracellular vesicles, among other applications described in conference abstracts and presentations that feature Seer’s technology.

The company also highlights the role of its platform in multi-omic and proteogenomic research. In communications around the American Society of Human Genetics (ASHG) and other scientific venues, Seer describes how its Proteograph Product Suite is used to complement genomics, helping researchers connect genetic variation to protein-level changes and disease mechanisms. Seer presents its technology as a critical component in studies that integrate proteomics with genomics and other data types to advance precision medicine and translational research.

Seer’s public materials point to the use of its platform in population-scale and large-cohort studies. For example, the company has described its involvement in a 20,000-sample population-scale proteomics study in collaboration with Korea University, as well as genome-wide association studies (GWAS) that use the Proteograph platform to map genetic determinants of protein abundance. These activities underscore Seer’s focus on scalability and its positioning of the Proteograph workflow as suitable for high-throughput proteomic analysis.

In addition to its platform components, Seer references a Technology Access Center in its financial disclosures, which is associated with service revenue. The company reports revenue from sales of Proteograph instruments and consumable kits, as well as service projects related to its Technology Access Center. This indicates that Seer’s business model includes both product sales and services that provide access to its technology for research customers.

Seer also reports ongoing third-party validation of its platform through publications, preprints, and scientific presentations. The company highlights multiple independent and collaborative studies presented at conferences such as the Human Proteome Organization (HUPO) World Congress and ASHG. These studies, as described in Seer’s news releases, use the Proteograph platform to uncover biomarkers, explore disease pathways, and compare mass spectrometry-based proteomics with affinity-based methods.

From a corporate structure perspective, Seer has disclosed that it previously had both Class A and Class B common stock. An 8-K filed in December 2025 reports that, pursuant to its Amended and Restated Certificate of Incorporation, each outstanding share of Class B common stock automatically converted into one share of Class A common stock at a specified time. Following this conversion, the Class B shares were retired and the company’s authorized capital was adjusted accordingly. Seer states that this conversion affected voting power—moving former Class B holders to one vote per share—but did not change the economic interests associated with the shares. The Class A common stock continues to trade under the SEER ticker.

Through its financial filings, Seer identifies itself as a Delaware corporation with its principal executive offices in Redwood City, California. The company reports revenue from products and services tied to its Proteograph platform and notes ongoing investments in research and development and selling, general, and administrative activities. Seer’s SEC filings and press releases also reference participation in healthcare and life sciences investor conferences, where company management discusses its business and platform.

Business Model and Operations

Based on Seer’s own descriptions, the company operates as a life sciences tools and technology provider focused on proteomics. Its revenue, as outlined in financial press releases, is derived from product revenue related to Proteograph instruments and consumable kits, and service revenue associated in part with Technology Access Center projects. Other revenue categories are also reported in its financial statements. This combination indicates a model that includes both instrument and consumable sales and service-based access to Seer’s technology.

Seer emphasizes that its Proteograph Product Suite is designed to be scalable and reproducible, enabling researchers to conduct deep proteomic profiling across large sample sets. The company’s communications describe the workflow as integrating hardware (automation instrumentation), consumables, engineered nanoparticles, and software into a coherent system, which it positions as addressing throughput and complexity challenges in proteomics research.

Role in Proteomics and Research Applications

In multiple news releases, Seer underscores the use of its platform in diverse research areas. At HUPO and other conferences, studies using the Proteograph workflow are described in cardiovascular research, aging-related decline, cancer biology, and other disease contexts. Presentations include work on plasma proteomics, tissue proteomics, extracellular vesicles, glycoproteomics, cerebrospinal fluid proteomics, and biomarker discovery.

Seer also highlights the use of its platform in proteogenomic and multi-omic studies. For example, a Nature Genetics publication referenced by Seer used the Proteograph platform for a genome-wide association study of mass spectrometry proteomics, focusing on peptide-level measurements and genetic determinants of protein abundance. Seer’s communications describe how such work can distinguish true biological effects from assay artifacts associated with certain affinity-based methods.

Capital Markets and Corporate Governance

Seer’s Class A common stock is listed on The Nasdaq Global Select Market under the symbol SEER, as confirmed in its 8-K filings. The company has disclosed matters related to Nasdaq listing rules, including an 8-K noting that, following its 2025 Annual Meeting of Stockholders, it would not be in compliance with Nasdaq Listing Rule 5605(c)(2)(A) regarding audit committee composition and financial sophistication. Seer states in that filing that it intends to rely on the cure period provided under Nasdaq rules and to evaluate board and committee composition to regain compliance within the allowed timeframe.

Seer’s 8-K filings also describe routine corporate governance matters such as the election of directors and ratification of the company’s independent registered public accounting firm at its annual meeting. The company reports that stockholders voted on director nominees and the appointment of Deloitte & Touche LLP as its independent auditor for the fiscal year ending December 31, 2025.

Stock Structure Changes

The December 2025 8-K details a conversion of all outstanding Class B common stock into Class A common stock, in accordance with the company’s certificate of incorporation. This automatic conversion occurred at a defined time following the fifth anniversary of the company’s first firm-commitment underwritten public offering that resulted in a stock exchange listing. After the conversion, the Class B shares were retired and the company filed a Certificate of Retirement in Delaware to reduce the authorized number of shares of capital stock and Class B common stock by the number of retired shares. Seer notes that the total number of outstanding shares of capital stock did not change as a result of the conversion, and that the Class A common stock continues to trade under the SEER ticker with the same CUSIP.

Use Cases and Customer Engagement

Seer’s public materials describe the Proteograph platform as being used by academic, clinical, and other research groups, as evidenced by independent and collaborative presentations at scientific conferences. The company references a growing number of third-party publications and preprints that use its technology, and notes that these works demonstrate the performance and applicability of the Proteograph workflow across a range of biological questions. Seer also highlights collaborations, such as the population-scale study with Korea University, as examples of how its platform is deployed in large-scale research efforts.

Regulatory and Intended Use

Across its press releases, Seer consistently states that its products are for research use only and are not intended for diagnostic procedures. This language clarifies the regulatory positioning of the Proteograph Product Suite as a research tool rather than a diagnostic device, which is an important distinction for users and investors evaluating the company’s market focus.

Summary

In summary, Seer, Inc. is a Nasdaq-listed life sciences company centered on deep, unbiased proteomics. Through its Proteograph Product Suite—which combines engineered nanoparticles, automation instrumentation, consumables, and analytical software—the company seeks to provide researchers with scalable, reproducible access to detailed proteomic data. Seer’s platform is used in a broad range of research areas, including cardiovascular disease, oncology, aging, and multi-omic studies that link genetic variation to protein-level changes. The company generates revenue from product and service offerings tied to this platform, maintains its headquarters in Redwood City, California, and continues to refine its capital structure and governance as disclosed in its SEC filings.